Drug Trial Radar · NCT03088059
Biomarker-based Study in R/M SCCHN
Last checked: Nov 20, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
340
Planned (sponsor's estimate)
Start
Nov 16, 2017
Primary completion
Jun 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Mar 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. Based on potential biomarkers and molecular alterations identified in the biopsy from the central platform, patients will be allocated in different cohorts. There will be biomarker-positive patient cohorts and immunotherapy cohorts.
Conditions
- Carcinoma, Squamous Cell of Head and Neck
Interventions
AfatinibDrug
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
PalbociclibDrug
Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
standard of careDrug
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
IPH2201Drug
protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
DurvalumabDrug
Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
NiraparibDrug
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
INCAGN01876Drug
INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival Rate (PFSR) at week 16Time frame: The Progression Free Survival Rate (PFSR) analysis will be performed at week 16 for each patient in cohorts 1, 2 and 3.
- Objective response Rate (ORR) at week 16Time frame: Objective response Rate (ORR) at week 16 will be performed at week 16 for each patient in cohort 4.
Locations
36 sites in 5 countries. Site status is shown where the registry gives one.
CHU Saint-Pierre-Site Porte de Hal
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium
Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame
Charleroi, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Hopital De Jolimont
Haine-Saint-Paul, Belgium
AZ Groeninge Kortrijk - Campus Kennedylaan
Kortrijk, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
GasthuisZusters Antwerpen - Sint-Augustinus
Wilrijk, Belgium
CHU Dinant Godinne - UCL Namur
Yvoir, Belgium
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
Bordeaux, France
Centre Georges-Francois-Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Nantes, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Institut de Cancerologie Strasbourg Europe
Strasbourg, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Gustave Roussy
Villejuif, France
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
IRCCS - Fondazione G. Pascale
Naples, Italy
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
Barcelona, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Hospital Clinico Universitario De Valencia
Valencia, Spain
University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre
Birmingham, United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, United Kingdom
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital
Glasgow, United Kingdom
Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital
London, United Kingdom
Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.